Bioluminescence Imaging of Bacterial Infections in Mice
JoVE Encyclopedia of Experiments
Microbiology
0 views • 2:02 min • February 2nd, 2026
Loading...
Overview
This study demonstrates a method for in vivo imaging of bacterial infections using genetically engineered bacteria that produce bioluminescence. The technique allows for the quantification of metabolically active bacteria at infection sites in anesthetized mice.
Key Study Components
Area of Science
- Microbiology
- Immunology
- In vivo imaging
Background
- Pathogenic bacteria can be genetically modified to express bioluminescent markers.
- Bioluminescence can indicate the presence of metabolically active bacteria.
- In vivo imaging techniques are essential for studying infections in live models.
- Safety protocols are critical when handling infected animals.
Purpose of Study
- To visualize and quantify bacterial infections in live mice.
- To assess the metabolic activity of bacteria at infection sites.
- To establish a reliable imaging protocol for future studies.
Methods Used
- Use of anesthetized mice with skin incisions infected with engineered bacteria.
- Application of the luxABCDE reporter system for bioluminescence.
- Imaging of infection sites using a bioluminescence imaging platform.
- Quantification of bioluminescence signal intensity to assess bacterial activity.
Main Results
- Successful visualization of bioluminescent signals at infection sites.
- Quantitative measurement of bacterial activity based on light intensity.
- Establishment of imaging parameters for optimal results.
- Demonstration of the method's effectiveness for in vivo studies.
Conclusions
- The bioluminescence imaging technique is effective for studying bacterial infections.
- This method provides insights into the metabolic state of pathogens.
- Future applications may include monitoring treatment responses in infections.
Frequently Asked Questions
What is the luxABCDE reporter system?
The luxABCDE reporter system is a genetic construct that enables bioluminescence in bacteria, allowing for visualization of their metabolic activity.
How are the mice prepared for imaging?
Mice are anesthetized and placed in a prone position on the imaging platform, following biosafety protocols.
What does the bioluminescence indicate?
Bioluminescence indicates the presence of metabolically active bacteria at the infection site.
What safety protocols are followed?
Biosafety level two containment protocols are followed for the transport and handling of infected mice.
How is the background signal measured?
A region of interest is created over a random area on the imaging platform to measure and subtract the background signal.
What are the imaging parameters adjusted during the experiment?
Parameters such as exposure time, binning, f-stop, and field of view are adjusted based on the experimental requirements.
Executive Industry Relevance
Non-invasive bioluminescence imaging of bacterial infections in live mice enables real-time quantification of pathogen dynamics, supporting translational infection model development. This approach enhances predictive confidence in preclinical anti-infective studies by providing quantitative, longitudinal readouts of bacterial metabolic activity. The method is positioned to inform early discovery, target validation, and risk-adjusted advancement decisions in anti-infective R&D portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct visualization and quantification of bacterial burden in vivo for hypothesis testing.
- Supports functional validation of anti-infective targets by monitoring metabolic activity at infection sites.
- Facilitates mechanistic de-risking by distinguishing active infection from background signal.
- Provides quantitative data to inform go/no-go decisions in early-stage anti-infective programs.
Screening & Assay Development
- Delivers standardized, reproducible imaging outputs for assay development and optimization.
- Enables high-content, quantitative assessment of infection progression and therapeutic intervention effects.
- Supports scalability and platform reuse for compound screening in live animal models.
- Improves reliability of efficacy evaluation by minimizing invasive sampling variability.
Translational & Preclinical Research
- Aligns preclinical infection models with disease-relevant endpoints through non-invasive monitoring.
- Enables longitudinal tracking of infection and therapeutic response in the same animal.
- Supports translational biomarker development by correlating bioluminescent signal with bacterial viability.
- Reduces animal use by enabling repeated measures and within-subject comparisons.
Pipeline & Workflow Integration
This imaging technique integrates into the discovery-to-preclinical continuum, bridging early infection model development with translational efficacy studies.
- Discovery Biology: Provides real-time, quantitative readouts for hypothesis testing and pathway clarification in infection models.
- Screening: Offers reproducible, quantitative outputs for compound efficacy assessment in vivo.
- Analytics: Enables statistical comparison of infection dynamics and intervention effects using photon flux measurements.
- Translational Research: Supports continuity from discovery through preclinical validation by aligning imaging endpoints with clinical infection parameters.
- Enterprise Reuse: Establishes a reusable imaging platform for diverse anti-infective research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in infection model studies.
- Operational Value: Standardizes infection quantification and enables scalable, reproducible workflows.
- Strategic Value: Improves go/no-go decision quality and capital efficiency in anti-infective portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of anti-infective candidates.
Implementation Considerations
- Requires expertise in genetic engineering of bacterial strains and in vivo imaging techniques.
- Needs access to bioluminescence imaging instrumentation and analytical software for photon quantification.
- Demands adherence to biosafety level two protocols for animal handling and transport.
- Standardization of imaging parameters and background subtraction is critical for cross-study comparability.
- Applicability may be limited to bacterial strains amenable to genetic modification with the luxABCDE system.
Biopharma FAQs
Why does null hypothesis testing matter for bioluminescent infection quantification?
Null hypothesis testing enables objective evaluation of whether observed changes in bioluminescent signal reflect true differences in bacterial burden or are due to random variation, supporting robust target validation and mechanistic de-risking in infection models.
How does independent variable isolation fit bioluminescent imaging workflows?
Isolating variables such as bacterial strain, infection site, and imaging parameters ensures that changes in photon flux are attributable to experimental interventions, enhancing interpretability and reproducibility in discovery-stage infection studies.
What do quantitative photon flux measurements enable in infection models?
Quantitative photon flux measurements provide a direct, non-invasive readout of metabolically active bacterial load, enabling longitudinal assessment of infection dynamics and therapeutic efficacy in preclinical models.
Why are replication requirements critical for cross-functional infection studies?
Replication ensures that bioluminescent imaging results are consistent and reliable across experiments and teams, facilitating cross-functional collaboration and data integration in anti-infective R&D pipelines.
What statistical analysis capabilities are needed before implementing bioluminescent imaging?
Robust statistical analysis tools are required to compare photon flux data, control for background signal, and determine significance thresholds, supporting confident decision-making in infection model development and compound evaluation.
09:29
In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
Related Videos
0 Views
05:52
In Situ Measurement and Correlation of Cell Density and Light Emission of Bioluminescent Bacteria
Related Videos
0 Views
07:19
Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo
Related Videos
0 Views
10:23
Using Luciferase to Image Bacterial Infections in Mice
Related Videos
0 Views
05:06
Bioluminescent Bacterial Imaging In Vivo
Related Videos
0 Views
04:35
Tracking Bacterial Infection Dynamics in a Mouse Using Bioluminescence
Related Videos
0 Views
02:12
Real-Time Imaging of Bacterial Infection in a Mouse Model Using Bioluminescence
Related Videos
0 Views
03:14
Visualization of Urinary Tract Infection in a Mouse Model Using Bioluminescence
Related Videos
0 Views
02:40
Bioluminescence Imaging of Acinetobacter baumannii-Infected Burn Wounds in Mice
Related Videos
0 Views
02:07
Bioluminescence Imaging to Track Bacterial Infection and Wound Healing in a Mouse Model
Related Videos
0 Views
Last updated: 15 August 2026